课题基金 / 基金详情

Enzympharmacotherapy for attenuating nicotine's psychoactive effects

Enzympharmacotherapy for attenuating nicotine's psychoactive effects
减轻尼古丁精神作用的酶药物疗法
批准号:
9342807
负责人:
Kim Janda
金额:
$24.06万
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-09-01 至 2018-08-31
关键词:
AbstinenceAddressAdultAlbuminsAlgorithmsAnimal ModelAntibodiesAntibody titer measurementAttenuatedBackBehavioral ModelBindingBiochemicalBiological AssayBlocking AntibodiesBloodBlood CirculationBrainBuffersCancer EtiologyCarbonCatabolismCatalysisCause of DeathCessation of lifeChronic Obstructive Airway DiseaseCigaretteClinicalClinical ResearchClinical TrialsCounselingDependenceDrug KineticsDrug TargetingEngineeringEnzymatic BiochemistryEnzyme StabilityEnzymesEpitopesFailureGoalsHalf-LifeHandHeart DiseasesHumanHypertensionImmunotherapyIntakeInterventionInvestigationKineticsMalignant NeoplasmsMarshalMeasuresMediatingMetabolismModelingMolecular WeightMonoamine OxidaseMutateNatureNicotineNicotine DependenceNicotinic ReceptorsNitrogenOutcomeOxidoreductaseOxygenPharmaceutical PreparationsPharmacodynamicsPharmacological TreatmentPharmacologyPhysiologicalPlacebosPolyethylene GlycolsPropertyProteinsPseudomonas putidaRattusReactionReportingResearchRewardsRodentRodent ModelSelf AdministrationSeriesSerumSiteSmokeSmokerSmokingSourceSpecificitySurfaceT-Lymphocyte EpitopesTestingTherapeuticTobaccoTobacco DependenceToxic effectVaccinesVariantWithdrawal Symptomaddictionbasebehavioral responsecardiovascular disorder riskcigarette smokingdisorder riskdopaminergic neurondrug of abuseefficacy evaluationexperimental studyhigh riskimmunogenicityimprovedin vivokillingsnanomolarnicotine oxidasenicotine replacementpre-clinicalpreferencepreventprotein aminoacid sequencesmoke inhalationsmoking cessationstemtherapeutic enzymethermostabilitytreatment strategytrendvaccine trial

项目摘要

项目成果

Kim Janda的其他基金

相似基金

相关文献

中文摘要
翻译
项目摘要/摘要。烟草成瘾是世界上第二大致死原因, 癌症和心脏病的单一最大原因。目前,全球有13亿吸烟者 每年造成约600万人死亡,考虑到目前的吸烟趋势,烟草将导致1000万人死亡 到2020年,每年的人口数量都会增加。每年,4200万成年吸烟者中有近一半试图戒烟;但由于 尼古丁具有高度成瘾性,成功率不到5%。帮助戒烟包括支持性戒烟 咨询、尼古丁替代和减少尼古丁奖赏和戒断的受体拮抗剂 症状。不幸的是,尼古丁替代疗法的长期效果仍然很差,并实现了 第一年后的禁酒率只有10%-20%。滥用药物疫苗诱导抗体阻断 尼古丁等药物的药理作用。到目前为止,用于戒烟的疫苗在 临床前动物模型的能力,以减少尼古丁介导的生理和行为反应。 然而,在临床研究中,这些疫苗未能衡量戒烟的显著差异 在干预组和安慰剂组之间。尼古丁疫苗的致命弱点是它们无法 产生足够高的效价(抗体浓度),以减少免费药物。鉴于以下限制, 免疫治疗,如何产生足够的药代动力学(PK)能力来防止快速尼古丁 吸食吸食毒品后的脑内分布?我们开始设想,要克服这种令人生畏的 需要极高的尼古丁抗体效价需要一种能够分解尼古丁的生物,而不是 简单地隔离毒品。手头的提案详细说明了一种细菌菌株,恶臭假单胞菌,它具有 进化到使用尼古丁作为其唯一的碳和氮来源。从这种细菌菌株中,我们发现了第一个 类酶,一种尼古丁氧化还原酶(NicA2),能高效地将尼古丁降解为 非精神活性产品。我们对这种酶的初步表征表明,它是一种很好的候选酶 我们称之为“酶药物疗法”。然而,像吸烟这样的策略的成功示范 戒烟治疗将需要掌握一些我们将作为具体目标进行的挑战。 主要包括:(1)以生化研究为手段,揭示尼卡A_2‘S的作用机制和特异性。(2) 改造NicA2以增加其在血清中的稳定性并降低免疫原性风险。(3)评估 NICA2及其变体在大鼠血/脑分布和行为模型中的疗效。我们的研究 主动是高风险的,然而,如果成功,酶药物疗法将解决 通过一种能够催化尼古丁降解的新生物进行基于抗体的治疗。
英文摘要
Project Summary/Abstract. Tobacco addiction is the second leading cause of death in the world and the single largest cause of cancer and heart disease. Currently there are 1.3 billion tobacco smokers worldwide resulting in an estimated 6 million deaths a year, and given present smoking trends, tobacco will kill 10 million people each year by 2020. Each year nearly half of the 42 million adult smokers attempt to quit; yet due to the highly addictive nature of nicotine, less than 5% succeed. Aids to smoking cessation include supportive counseling, nicotine replacement and receptor antagonists that reduce nicotine reward and withdrawal symptoms. Unfortunately, long-term outcomes for nicotine replacement therapies remain poor and achieve an abstinence rate of only 10-20% after the first year. Drug of abuse vaccines induce antibodies that block the pharmacological effects of drugs like nicotine. To date, vaccines for smoking cessation have shown promise in preclinical animal models for their ability to diminish nicotine-mediated physiological and behavioral responses. However, in clinical studies these vaccines failed to measure significant differences in smoking abstinence between the intervention and placebo groups. The Achilles heel with nicotine vaccines has been their inability to generate high enough titers (antibody concentration) to reduce free drug. In view of the limitations with immunotherapy, how can sufficient pharmacokinetic (PK) capacity be engendered to prevent rapid nicotine distribution into the brain after smoked drug intake? We came to envision that to overcome such forbidding needs of extremely high nicotine-antibody titers would require a biologic able to catabolize nicotine rather than simply sequestering the drug. The proposal at hand details a bacterial strain, Pseudomonas putida, which has evolved to use nicotine as its sole source of carbon and nitrogen. From this bacterial strain we disclose a first in class enzyme, a nicotine oxidoreductase (NicA2) that is highly efficient at degrading nicotine to a non-psychoactive product. Our initial characterization of the enzyme indicates it to be an excellent candidate for what we term “enzympharmacotherapy”. Yet, successful demonstration of such a strategy as a smoking cessation therapy will require mastery of a number of challenges that we will undertake as specific aims including: (1) Biochemical studies as a means to unravel NicA2's mechanism of action and specificity. (2) Engineering NicA2 to increase its stability in serum and reduce immunogenicity liabilities. (3) Evaluation of the efficacy of NicA2 and variants in rats using blood/brain distribution, and behavioral models. Our research initiative is high-risk, however, if successful, enzympharmacotherapy will address the shortcomings of antibody-based therapeutics through a new biologic capable of catalyzing nicotine's degradation.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
An Enzyme-Based Antidote for Acute Nicotine Toxicity
  • 批准号:
    10790758
  • 项目类别:
  • 资助金额:
    $27.15万
  • 财政年份:
    2023
  • 负责人:
    Kim Janda
  • 依托单位:
Discovering modulators of exonucleases PLD3 and PLD4 for immunoregulation
  • 批准号:
    10620110
  • 项目类别:
  • 资助金额:
    $22.19万
  • 财政年份:
    2022
  • 负责人:
    Kim Janda
  • 依托单位:
Discovering modulators of exonucleases PLD3 and PLD4 for immunoregulation
  • 批准号:
    10353980
  • 项目类别:
  • 资助金额:
    $26.63万
  • 财政年份:
    2022
  • 负责人:
    Kim Janda
  • 依托单位:
High-Throughput Screen for the Oncoprotein MYC
  • 批准号:
    10276232
  • 项目类别:
  • 资助金额:
    $43.29万
  • 财政年份:
    2021
  • 负责人:
    Kim Janda
  • 依托单位:
海外基金